Compare Uranium Energy Corp (UEC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Uranium Energy Corp vs GeneDx Holdings Corp — how do they compare? Uranium Energy Corp trades at $11.63 (market cap $5.74B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Uranium Energy Corp is far larger — about 2.2× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| UEC | WGS | |
|---|---|---|
Market Cap | $5.74B | $2.58B |
Sector | Energy | Technology |
52-Week High | $20.14 | $167.51 |
52-Week Low | $9.04 | $34.51 |
Enterprise Value | $5.25B | $2.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UEC is trading at $11.89, up 3.03% today, with a bullish technical signal despite negative profitability metrics. The company reported a net loss of $87.66 million in 2025 with revenue of $66.84 million, though it beat Q4 2025 EPS expectations. Analyst sentiment remains strongly positive with 87.5% buy ratings, supported by institutional interest including BlackRock's recent $432.68 million investment.
The outlook for UEC is mixed, with strong analyst support and nuclear energy tailwinds offset by persistent losses and negative margins. Key risks include execution challenges and uranium price volatility, while opportunities lie in the growing nuclear power sector and institutional backing. The stock trades near recent support levels with technical indicators suggesting potential near-term strength.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
